A major obstacle to the development of safer and more effective pain treatments is the poorly defined nature of the different pathways involved in chronic pain. The applicant team bring together a unique set of research expertise in using neurotoxins to define, at the molecular level, how the nervous system functions. The applicants also share a common interest in understanding and improving treatments for pain, especially chronic pain which continues to remain poorly managed Through a focus on ....A major obstacle to the development of safer and more effective pain treatments is the poorly defined nature of the different pathways involved in chronic pain. The applicant team bring together a unique set of research expertise in using neurotoxins to define, at the molecular level, how the nervous system functions. The applicants also share a common interest in understanding and improving treatments for pain, especially chronic pain which continues to remain poorly managed Through a focus on pain research, the Program will significantly enhance the scope of existing multidisciplinary collaborations between the Cis Lewis Alewood, Adams and Christie, which have already made a considerable impact in the fields of pharmacology and neuroscience. The CIs also have considerable experience in the development of pain therapeutics, having discovered two conopeptides now under commercial development with AMRAD (AM336) and Xenome Ltd (Xen2174). This Program will discover and use highly selective conopeptides such as these to dissect the pharmacology of peripheral pain pathways and their projections into the central nervous system, and to identify and characterise new targets amenable to drug intervention. The long-term goal of the Program is to discover new targets in pain pathways and develop conopeptides that act on these targets in animal models of chronic pain. These molecules will be optimised within the Program to the point where they can be considered for pre-clinical development in collaboration with commercial partners.Read moreRead less
Headache Prophylaxis By Cortico-brainstem Mechanisms
Funder
National Health and Medical Research Council
Funding Amount
$616,437.00
Summary
In this project we hope to discover the cause of migraine headache. Many triggers lead to migraine, but we do not know how. We believe the triggers produce a defect in pain control by the brainstem, which normally keeps sensation from the head below the pain threshold. In migraine, trigger factors acting high in the brain open a pain control gate lower in the brain, producing a migraine headache. If we can prove this, we can develop therapies that will prevent migraine before it starts.
Role Of GAT-1 Transporter Channels In Opioid Dependence
Funder
National Health and Medical Research Council
Funding Amount
$524,456.00
Summary
Opioid drugs including heroin and morphine are very addictive. After cessation of chronic use of these drugs an intensely unpleasant withdrawal syndrome develops that contributes to relapse. Brain mechanisms that produce withdrawal are still poorly understood. The present work will determine the pathological cellular and molecular mechanisms that produce withdrawal in inhibitory brain nerve cells known to be involved in generating withdrawal discomfort and relapse to compulsive drug use.
Improving the function of GABA-A receptors is a key property of several classes of clinically important drugs including benzodiazepines and many anticonvulsants. However, the binding sites and molecular mechanisms of these drugs remain poorly understood. Using compounds similar to those in green tea, we will determine the molecular mechanism of these drugs. This understanding will lead to the development of better drugs for treatment of anxiety, depression, epilepsy, insomnia & schizophrenia.
Novel Delta Receptor Expression In Opioid Tolerant/dependent Neurons
Funder
National Health and Medical Research Council
Funding Amount
$370,350.00
Summary
Opioids such as morphine and heroin act on specific molecular targets, or receptors, in the brain. Long term use of opioids produce changes in brain receptor systems that greatly diminish the effects of these drugs (tolerance), as well as producing an adverse withdrawal syndrome on cessation of use (physical dependence). The present proposal will identify the mechanisms of adaptations in cellular function in nerve cells critical for these changes. In particular, we have identified enhanced sensi ....Opioids such as morphine and heroin act on specific molecular targets, or receptors, in the brain. Long term use of opioids produce changes in brain receptor systems that greatly diminish the effects of these drugs (tolerance), as well as producing an adverse withdrawal syndrome on cessation of use (physical dependence). The present proposal will identify the mechanisms of adaptations in cellular function in nerve cells critical for these changes. In particular, we have identified enhanced sensitivity of receptor, the delta receptor, that is closely related to the opioid receptor but is not a target for heroin or morphine. We will identify the mechanisms of enhanced activity of this receptor after chronic use of morphine with a view to tergeting therapeutics to manage tolerance and physical dependence in opioid addicts and chronic pain patients.Read moreRead less
Identifying Novel Molecular Targets For Treating Chronic Pain.
Funder
National Health and Medical Research Council
Funding Amount
$402,952.00
Summary
Chronic pain is very common, with one in five Australians suffering long-term pain that is serious enough to cause disability. It is extraordinarily difficult to treat. Medicines used to treat normal pain symptoms are usually ineffective on chronic pain patients because the cause of the pain is different. The aim of this project is to identify new drug targets in the spinal cord that are specific for chronic pain so we can develop new medicines to reverse the symptoms safely and effectively.
Research Fellowship: Understanding G Protein-coupled Receptors (GPCRs)
Funder
National Health and Medical Research Council
Funding Amount
$444,177.00
Summary
This project focuses on drug action at G protein-coupled receptors (GPCRs), the largest class of drug targets. It builds on key discoveries by the applicant that novel sites on GPCRs can be targeted by small molecules in a selective manner, thus minimizing side effects and maximizing therapeutic efficacy. Because this approach can work across most GPCR families, the relevance to the pharmaceutical industry and GPCR-related diseases, such as schizophrenia and diabetes, is very high.
Viability And Efficacy Of Implantable Biopolymer Based Anticonvulsant Delivery Systems In Rat Models Of Focal Epilepsy.
Funder
National Health and Medical Research Council
Funding Amount
$64,631.00
Summary
Recurrent seizures arising from abnormal brain activity are call epilepsy. Presently, epilepsy is treated using medicines by mouth. These often cause side effects affecting other body systems such as liver. Such effects can make patients ill or prevent them using particular drugs for epilepsy. Developing ways to deliver epilepsy medication directly to brain may allow better control of epileptic seizures with fewer side effects. We hope to develop a new such system using rats with epilepsy.
I am a neuroscientist, studying fundamental mechanisms related to addiction. A major feature of my research is the neuropharmacological characterisation of potential novel therapeutic strategies to combat drug-seeking behaviour